Zur Kurzanzeige

dc.contributor.authorAlho, Hannu
dc.contributor.authorDematteis, Maurice
dc.contributor.authorLembo, Danilo
dc.contributor.authorMaremmani, Icro
dc.contributor.authorRoncero Alonso, Carlos 
dc.contributor.authorSomaini, Lorenzo
dc.date.accessioned2025-01-29T11:06:59Z
dc.date.available2025-01-29T11:06:59Z
dc.date.issued2020
dc.identifier.citationAlho, H., Dematteis, M., Lembo, D., Maremmani, I., Roncero, C., & Somaini, L. (2020). Opioid-related deaths in Europe: Strategies for a comprehensive approach to address a major public health concern. International Journal of Drug Policy, 76, 102616.es_ES
dc.identifier.issn1873-4758
dc.identifier.issn0955-3959
dc.identifier.urihttp://hdl.handle.net/10366/163070
dc.description.abstract[EN]Use of illicit opioids and misuse of prescription opioids are the main causes of drug-related deaths across the world, and the continuing rise in opioid-related mortality, especially affecting North America, Australia and Europe, is a public health challenge. Strategies that may help to decrease the high levels of opioid-related mortality and morbidity and improve care across Europe include risk assessment and interventions to improve the use of opioid analgesics, e.g. prescription drug-monitoring programmes, education on pain management to reduce opioid prescribing, and the implementation of evidence-based primary prevention programmes to reduce the demand for opioids. For patients who develop opioid use disorder (a chronic and relapsing problematic use of opioids that causes clinical impairment or distress), treatment combining opiate receptor full or partial agonist medications for opioid-use disorder (MOUD) with psychosocial interventions is essential. However, in Europe a substantial proportion of the 1.3 million high-risk opioid users (defined as injecting drug use or regular use of opioids, mainly heroin) remain outside of dedicated treatment programmes. More widespread and easier access to MOUD could reduce mortality levels; via approaches such as primary care-led treatment models, and efforts to improve patient retention and adherence to treatment programmes. Other harm-reduction strategies, such as the use of MOUD at optimal doses, the provision of take-home naloxone, the introduction of supervised drug-consumption facilities, and patient education to reduce the risk of overdose may also be beneficial.es_ES
dc.language.isoenges_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectoverdosees_ES
dc.subjectOpiatees_ES
dc.subjectOpioid use disorderes_ES
dc.subjectMortalityes_ES
dc.titleOpioid-related deaths in Europe: Strategies for a comprehensive approach to address a major public health concernes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.1016/j.drugpo.2019.102616es_ES
dc.identifier.doi10.1016/J.DRUGPO.2019.102616
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.pmid31855706
dc.journal.titleInternational Journal of Drug Policyes_ES
dc.volume.number76es_ES
dc.page.initial102616es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Dateien zu dieser Ressource

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Solange nicht anders angezeigt, wird die Lizenz wie folgt beschrieben: Attribution-NonCommercial-NoDerivatives 4.0 Internacional